The Lush Prize aims to stimulate worldwide research in 21st century toxicology with a view to replacing animal tests completely.
In 2019 Lush Prize decided to re-focus its criteria for awarding its science prizes on projects most likely to lead to practical non-animal tests which could be accepted by regulators.
We think the most promising approaches include:
- adverse outcome pathways
- organs on chips, and
- computational toxicology
Lush Prize is also particularly interested in human relevant adverse outcome pathways for systemic toxicology or developmental toxicology.
Science Prize funding is £50,000.
The next awards will take place in 2020.
Stay up to date about entry dates and other news by signing up for occasional email updates about the Prize:
Dr Dan Huh, The BIOLines Research Group, University of Pennsylvania, USA, (£50,000)
Microengineered bio-mimicry of human physiological systems.
Professor Jennifer Lewis, Lewis Bioprinting Team – Harvard University, USA, (£50,000)
Their research seeks to completely eliminate the use of animals by the pharmaceutical and cosmetic industries. Towards this goal, the research team at the Wyss Institute at Harvard University has developed a multimaterial bioprinting platform for fabricating 3D human organ-on-chip models.
Dr Suhyon Lee – Biosolution Co Ltd, South Korea, Commendation
Developing human tissue models using tissue engineering technology. The models that are developed/manufactured here are reconstructed human tissue models by 3D culturing human derived cells.
Prof Marcel Leist, University of Konstanz / CAAT-Europe, Germany (£40,000)
This group focuses on the development of toxicological tests that are based on the use of human cells. Their vision is that eventually, when all these tests are established, the hazard can be predicted, based on an in vitro test battery.
Dr. Daniele Zink and Dr. Lit-Hsin Loo, (A*STAR), Singapore (£10,000)
A research team led by Dr Daniele Zink from the Institute of Bioengineering and Nanotechnology and Dr Lit-Hsin Loo from the Bioinformatics Institute of the Agency for Science, Technology and Research in Singapore have developed animal-free methods that can accurately predict the toxic effects of chemicals on the human kidney.
Oncotheis, Switzerland (£25,000)
Oncotheis have engineered an innovative human lung cancer tissue culture model to test in vitro both the effectiveness and the toxicity of investigational therapeutics while sparing the lives of animals.
Prof Michael L. Shuler & Team, USA (£25,000)
Professor Michael L. Shuler, Cornell University & Hesperos
Asst. Professor Mandy B. Esch, Syracuse University
Asst. Professor Gretchen J. Mahler, SUNY Binghampton University
Professor Tracy Stokol, Cornell University
Dr James Hickman, University of Central Florida & Hesperos
Since 1989 they have developed in vitro systems to predict human response to drugs by using physiologically-based pharmacokinetic (PBPK) models to guide the development of experimental systems that mimic human response to drugs. These systems have been called “Body-on-a-Chip” systems.
Professor Roland Grafström and Dr. Pekka Kohonen, Karolinska Institutet, Sweden (£50,000)
The Grafström laboratory has developed a cancer biology work and Tox21 Century Toxicology-inspired approach for replacing toxicity testing in animals with informatics-driven data analysis of human cell cultures exposed to toxic agents.
QSAR and Molecular Modelling Group, Liverpool John Moores University, UK (£25,000)
For their work developing computational alternatives to animal testing to predict the effects of chemicals.
The Lung & Particles Research Group, Cardiff University, UK (£25,000)
For their work developing non-animal replacement models of the human respiratory system for inhalation toxicology applications.
The Institute for Health and Consumer Protection, European Commission Joint Research Centre, Italy (£50,000)
For its work on toxicity pathways in heptatoxicology and developmental toxicology.